Obermatt
See Similar Stocks →

Mediwound

NMQ:MDWD · IL0011316309
PharmaceuticalsSmall

360

25
Profit price68
Owner Earnings Yield1
Dividend Yield1
Price/Sales10
EV / Gross Profit8
Price/Book1
Return on Capital13
Cash Return on Capital10
Return on Equity10
EBIT Margin1
Gross Profitability18
Accruals82
Owner Earnings Margin10
Sales growth83
Profit growth14
Reinvestment60
Price momentum17
Debt load71
Refinancing10
Debt Payback1
Liquidity16
Analyst ratings67
Opinion Changes50
Price Target Upside66
Market mood71
Value Creation4/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Mediwound doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryIsrael
IndustryPharmaceuticals
SizeSmall
TypePublic Company
ExchangeNASDAQGM
Founded2000
Employees98
Websitemediwound.com
ISINIL0011316309
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
Health DiagnosticsDiabetesDermatologyOncologySurgeryBiotechnologyManufacturingMedical Device

Description

MediWound Ltd., a biopharmaceutical company, which develops, manufactures, and commercializes novel, bio-therapeutic, non-surgical solutions for tissue repair and regeneration. The company's solutions selectively remove non-viable hazardous tissue w…

Analysis

Weak and unloved

MediWound Ltd. scores below average on quality and is priced accordingly, a low-conviction position in either direction.

Valuation data is not available for this company.

Growth is moderate; the safety picture is adequate. The company scores 4/20 on our value-creation score: not creating value. Analysts lean positive.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
14
2026

All-time high

20

Mar 2026

All-time low

14

Jun 2026

Average rank

17

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
10
—
—
—
Price/Earnings
82
—
—
—
Price/Book
1
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
12
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Mediwound with its peers
GH Research
NMQ:GHRS
57
CountryIreland
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
OKYO Pharma
NAQ:OKYO
40
CountryUK
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
Pharming
AEX:PHARM
77
CountryNetherlands
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Barratt Redrow
LSE:BTRW
75
CountryUK
IndustryHousehold Durables
SizeLarge
Full Stock Analysis →
InMode
NSQ:INMD
86
CountryIsrael
IndustryHealth Care Equipment & Supplies
SizeSmall
Full Stock Analysis →
Nano-X Imaging
NMQ:NNOX
26
CountryIsrael
IndustryHealth Care Providers & Services
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →